12:00 AM
 | 
Aug 15, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ATB-346: Phase II data

An open-label, Canadian Phase II trial in 12 patients with OA of the knee showed that once-daily 250 mg oral ATB-346 reduced Western...

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >